TY  - JOUR
A1  - Klotz, Barbara
A1  - Mentrup, Birgit
A1  - Regensburger, Martina
A1  - Zeck, Sabine
A1  - Schneidereit, Jutta
A1  - Schupp, Nicole
A1  - Linden, Christian
A1  - Merz, Cornelia
A1  - Ebert, Regina
A1  - Jakob, Franz
T1  - 1,25-Dihydroxyvitamin D3 Treatment Delays Cellular Aging in Human Mesenchymal Stem Cells while Maintaining Their Multipotent Capacity
JF  - PLoS ONE
N2  - 1,25-dihydroxyvitamin D3 (1,25D3) was reported to induce premature organismal aging in fibroblast growth factor-23 (Fgf23) and klotho deficient mice, which is of main interest as 1,25D3 supplementation of its precursor cholecalciferol is used in basic osteoporosis treatment. We wanted to know if 1,25D3 is able to modulate aging processes on a cellular level in human mesenchymal stem cells (hMSC). Effects of 100 nM 1,25D3 on hMSC were analyzed by cell proliferation and apoptosis assay, beta-galactosidase staining, VDR and surface marker immunocytochemistry, RT-PCR of 1,25D3-responsive, quiescence-and replicative senescence-associated genes. 1,25D3 treatment significantly inhibited hMSC proliferation and apoptosis after 72 h and delayed the development of replicative senescence in long-term cultures according to beta-galactosidase staining and P16 expression. Cell morphology changed from a fibroblast like appearance to broad and rounded shapes. Long term treatment did not induce lineage commitment in terms of osteogenic pathways but maintained their clonogenic capacity, their surface marker characteristics (expression of CD73, CD90, CD105) and their multipotency to develop towards the chondrogenic, adipogenic and osteogenic pathways. In conclusion, 1,25D3 delays replicative senescence in primary hMSC while the pro-aging effects seen in mouse models might mainly be due to elevated systemic phosphate levels, which propagate organismal aging.
KW  - perspectives
KW  - bone marrow
KW  - mutant mice
KW  - oxidative stress
KW  - transcription factors
KW  - vitamin-D-receptor
KW  - differentiation
KW  - tissue
KW  - 2',7'-dichlorofluorescin
KW  - homeostasis
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-133392
VL  - 7
IS  - 1
ER  - 
TY  - JOUR
A1  - Jakob, Franz
A1  - Ebert, Regina
A1  - Rudert, Maximilian
A1  - Nöth, Ulrich
A1  - Walles, Heike
A1  - Docheva, Denitsa
A1  - Schieker, Matthias
A1  - Meinel, Lorenz
A1  - Groll, Jürgen
T1  - In situ guided tissue regeneration in musculoskeletal diseases and aging
JF  - Cell and Tissue Research
N2  - In situ guided tissue regeneration, also addressed as in situ tissue engineering or endogenous regeneration, has a great potential for population-wide “minimal invasive” applications. During the last two decades, tissue engineering has been developed with remarkable in vitro and preclinical success but still the number of applications in clinical routine is extremely small. Moreover, the vision of population-wide applications of ex vivo tissue engineered constructs based on cells, growth and differentiation factors and scaffolds, must probably be deemed unrealistic for economic and regulation-related issues. Hence, the progress made in this respect will be mostly applicable to a fraction of post-traumatic or post-surgery situations such as big tissue defects due to tumor manifestation. Minimally invasive procedures would probably qualify for a broader application and ideally would only require off the shelf standardized products without cells. Such products should mimic the microenvironment of regenerating tissues and make use of the endogenous tissue regeneration capacities. Functionally, the chemotaxis of regenerative cells, their amplification as a transient amplifying pool and their concerted differentiation and remodeling should be addressed. This is especially important because the main target populations for such applications are the elderly and diseased. The quality of regenerative cells is impaired in such organisms and high levels of inhibitors also interfere with regeneration and healing. In metabolic bone diseases like osteoporosis, it is already known that antagonists for inhibitors such as activin and sclerostin enhance bone formation. Implementing such strategies into applications for in situ guided tissue regeneration should greatly enhance the efficacy of tailored procedures in the future.
KW  - in situ guided tissue regeneration
KW  - stem cells
KW  - scaffolds
KW  - regenerative medicine
KW  - mesenchymal tissues
Y1  - 2012
U6  - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-124738
VL  - 347
IS  - 3
ER  -